Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Completed · Phase 2
Conditions studied: Blood Cancer, Multiple Myeloma
In brief
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body irradiation along with immunosuppression using cyclosporine and mycophenolate mofetil; suppress graft-vs-host and host-vs-graft reactions to allow a mixed chimeric state to be established, encourage tolerance and prevent graft-vs-host disease (GvHD) during the mixed chimerism period and use donor lymphocyte infusions to convert the patient to a full chimera while developing a graft-vs-tumor effect.
Key facts
- Study ID
- NCT00185614
- Run by
- Wen-Kai Weng
- People needed
- 63
- Starts
- 2000-08-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2018-01-18
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.